Novo Nordisk’s Revolutionary Drug Amycretin: A Game Changer For People Struggling With Obesity

Published: 21 Jun 2025
The ground-breaking obesity drug, Amycretin, made by Novo Nordisk, is showing promising results in clinical trials - offering hope to millions of overweight individuals worldwide.

The obesity crisis could finally be tackled with Amycretin, a potential game-changer invented by Danish pharmaceutical company, Novo Nordisk. Data from clinical trials indicates that Amycretin, when administered both subcutaneously and orally, shows significant potential for weight loss among overweight people. In addition to its effectiveness, Amycretin’s safety profile is in tune with other GLP-1 and amylin receptor agonists, making it well-tolerated amongst patients during conducting trials.Amycretin’s innovation comes from its unique combination of GLP-1 and amylin receptor agonism biology within a single molecule, making it the first treatment of its kind. Patients who received varying doses demonstrated a significant reduction in weight compared to those given a placebo, with no observed plateauing in weight loss even after treatment periods of up to 36 weeks. This could suggest that longer treatment durations may potentially lead to even more weight loss.It wasn’t just the weight loss that was encouraging; the safety profile of the drug was reassuring too. The treatment-related adverse effects inclined with the dose increase and were primarily gastrointestinal, in line with early-phase studies of similar receptor agonists. Additionally, they were mostly mild to moderate and fully resolved by the end of the study. It is worth noting, the majority of participants who discontinued the trial did so for non-TEAE (Treatment Emergent Adverse Events) reasons.These trial results on Amycretin were presented at the American Diabetes Association’s scientific sessions and published in the revered Lancet medical journal, putting Amycretin on the map for its potential in revolutionising obesity treatment.